Acrivon Therapeutics Business Summary

Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company that operates a precision medicine business model focused on developing oncology therapies matched to specific patient populations. The company primarily generates value through the advancement of its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which utilizes AI-driven phosphoproteomics to identify "OncoSignature" biomarkers that predict patient response. While currently pre-revenue and reliant on equity financing and strategic partnerships, Acrivon’s pipeline is led by ACR-368 (prexasertib), a CHK1/2 inhibitor in Phase 2b trials for endometrial cancer, alongside ACR-2316, a dual WEE1/PKMYT1 inhibitor. In the competitive landscape of targeted oncology, Acrivon contends with firms such as Repare Therapeutics, C4 Therapeutics, and Molecular Partners, distinguishing itself by moving beyond traditional genomics to analyze active protein signaling pathways for superior patient stratification. The company was co-founded by CEO Peter Blume-Jensen, M.D., Ph.D., and EVP Kristina Masson, Ph.D., M.B.A., both of whom bring extensive pedigrees in oncology R&D and proteomics. Dr. Blume-Jensen previously held senior leadership roles at Merck & Co. and Daiichi Sankyo, while Dr. Masson specializes in biomarker discovery and business operations. The executive team is further strengthened by CFO Adam D. Levy, Ph.D., M.B.A., formerly of Zentalis and Gilead Sciences, and Chief Medical Officer Mansoor Raza Mirza, M.D., a renowned leader in gynecologic oncology. Acrivon is backed by a robust roster of institutional investors, including Wellington Management, Goldman Sachs, and Citadel, and its board features industry veterans such as Charles Baum and Sharon Shacham, providing deep clinical and commercial expertise.